In 2001 the Institute of Medicine named patient centered care one of six keys to delivering high-quality care. How can pharma companies keep patients center stage while in the midst of a digital transformation? Precision’s Marty Samples discusses the four fundamentals of patient-centered care and how pharma marketers can use digital to execute on them.
The Brazilian health system, a mix of private and public payers, predominantly relies on a fee for service model. In order to meet the health care needs of a growing population but also control spending, Brazil needs to evolve its payment models toward value-based health care. Precision’s Jeremy Schafer and 2iM Inteligencia Medica’s Cesar Abicalaffe analyze the lessons the Brazilian healthcare system can learn from the United States, where value-based care is slowly but surely becoming the norm.
Pharmaceutical manufacturers and payers have been involved in a back and forth dance regarding patient cost share practices – each action is met with a reaction. Precision’s Jeremy Schafer looks at the complex battle between pharmaceutical manufacturers and payers for balance between medication access and budget management.
Access challenges to cell and gene therapy are well documented. Precision’s Christina Poschen and David Carr discuss how some innovative manufacturers are moving away from the role of being purely a researcher and manufacturer and toward involvement at the point of diagnosis through manufacturing and delivery to patient access support in order to address those challenges head on.
Who typically has responsibility for Identity and Access Management within health plan organizations, and how does this role impact or protect their healthcare analytics objectives? Precision’s Dominic Galante contributes to the Thought Leaders Corner in this month’s Care Analytics News.
Over the past decade, healthcare has slowly been moving from a focus on volume to value based healthcare. With the COVID-19 pandemic, compelling aspects of alternative payment models (APM) are causing providers, payers, and pharmaceutical manufacturers to take notice. Precision’s Elizabeth Oyekan identifies four emerging trends in APM practices that are enabling APMs to be better prepared to deliver high-quality and more affordable care during the COVID-19 pandemic.
COVID-19 led to the cancellation of in-person meetings and conferences where pharmaceutical manufacturers connect with payers. Precision’s Andrew Cournoyer discusses our research results on the effects of the shift to virtual negotiations between pharma and payers, and the challenges they face going forward.
Over the past decade, healthcare has slowly been moving from a focus on volume to value based healthcare. With the COVID-19 pandemic, compelling aspects of alternative payment models (APM) are causing providers, payers, and pharmaceutical manufacturers to take notice. Precision’s Elizabeth Oyekan identifies four emerging trends in APM practices that are enabling APMs to be better prepared to deliver high-quality and more affordable care during the COVID-19 pandemic.
As more Integrated Delivery Networks (IDNs) and employers move towards contracting directly with each other for health care services, the ripple effects are being felt in the supply chain and in old relationships with other players, including PBMs and pharmaceutical manufacturers. Precision’s Avi Mamidi discusses the benefits and obstacles of cutting out health insurance middlemen and moving towards direct employer-IDN partnerships.
By Kathy Lang, PhD; Jason Shafrin, PhD
PRECISIONheor
What is the right price for a new treatment for COVID-19: ISPOR’s “value flower” or the traditional QALYs approach? Precision’s Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments – in cases like COVID-19 – which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
